Semaglutide subcutaneous - Novo Nordisk
At a glance
- Drug Originator Novo Nordisk
- Drug Class Antidementias; Antihyperglycaemics; Glucagon-like peptides; Hepatoprotectants; Obesity therapies; Urologics; Vascular disorder therapies
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
- USA Patent Applicants NOVO
- USA Patents 36
- NDAs 2
- International Patents 292
- Patent Applications 714
Table of Contents
Disclaimer